Published in J Allergy Clin Immunol on January 27, 2006
Human innate immune responses to hexamethylene diisocyanate (HDI) and HDI-albumin conjugates. Clin Exp Allergy (2008) 1.01
Developments in laboratory diagnostics for isocyanate asthma. Curr Opin Allergy Clin Immunol (2007) 0.99
Choice of mouse strain influences the outcome in a mouse model of chemical-induced asthma. PLoS One (2010) 0.95
Environmental isocyanate-induced asthma: morphologic and pathogenetic aspects of an increasing occupational disease. Int J Environ Res Public Health (2011) 0.93
Pro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease? Clin Exp Allergy (2010) 0.92
Pathogenesis and disease mechanisms of occupational asthma. Immunol Allergy Clin North Am (2011) 0.90
Is specific IgE antibody analysis feasible for the diagnosis of methylenediphenyl diisocyanate-induced occupational asthma? Int Arch Occup Environ Health (2012) 0.86
Evidence for allergic reactions in isocyanate asthma. J Allergy Clin Immunol (2007) 0.84
Interferon-γ promoter is hypermethylated in blood DNA from workers with confirmed diisocyanate asthma. Toxicol Sci (2013) 0.80
Occupational airborne exposure, specific sensitization and the atopic status: evidence of a complex interrelationship. J Occup Med Toxicol (2013) 0.80
Update on the Pathogenic Mechanisms of Isocyanate-induced Asthma. World Allergy Organ J (2008) 0.79
Gene expression in nasal lavage from hairdressers exposed to persulphate. Int Arch Occup Environ Health (2009) 0.75
Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med (2007) 4.58
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
The 4-metre gait speed in COPD: responsiveness and minimal clinically important difference. Eur Respir J (2013) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Protective effect of fruits, vegetables and the Mediterranean diet on asthma and allergies among children in Crete. Thorax (2007) 1.98
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol (2007) 1.84
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Tregs and allergic disease. J Clin Invest (2004) 1.64
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Modified Th2 responses at high-dose exposures to allergen: using an occupational model. Am J Respir Crit Care Med (2006) 1.52
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Another plausible explanation for mist inhaler's toxicity. BMJ (2011) 1.38
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Gene-environment interaction for childhood asthma and exposure to farming in Central Europe. J Allergy Clin Immunol (2011) 1.30
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med (2007) 1.26
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22
Personal exposure and long-term health effects in survivors of the union carbide disaster at bhopal. Environ Health Perspect (2002) 1.20
Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Protection from childhood asthma and allergy in Alpine farm environments-the GABRIEL Advanced Studies. J Allergy Clin Immunol (2012) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review. Respirology (2012) 1.07
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
A prospective study of Fel d1 and Der p1 exposure in infancy and childhood wheezing. Am J Respir Crit Care Med (2004) 1.05
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax (2006) 1.03
Early-life allergen exposure and atopy, asthma, and wheeze up to 6 years of age. Am J Respir Crit Care Med (2007) 1.03
Nitrogen dioxide is not associated with respiratory infection during the first year of life. Int J Epidemiol (2004) 1.02
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
Health effects of real-world exposure to diesel exhaust in persons with asthma. Res Rep Health Eff Inst (2009) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Reliability and validity of 4-metre gait speed in COPD. Eur Respir J (2012) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Prenatal dichlorodiphenyldichloroethylene (DDE) and asthma in children. Environ Health Perspect (2005) 0.99
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Standards of care for occupational asthma: an update. Thorax (2011) 0.94
Early-life domestic aeroallergen exposure and IgE sensitization at age 4 years. J Allergy Clin Immunol (2006) 0.94
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
Interpreting the results of the amplified Mycobacterium tuberculosis direct test for detection of M. tuberculosis rRNA. J Clin Microbiol (2003) 0.91
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis. Respir Med (2008) 0.89
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89
Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88
Recorded infections and antibiotics in early life: associations with allergy in UK children and their parents. Thorax (2007) 0.87
Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87
The asbestos disease epidemic: here today, here tomorrow. Thorax (2011) 0.86
Welding, longitudinal lung function decline and chronic respiratory symptoms: a systematic review of cohort studies. Eur Respir J (2012) 0.86
Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85
Asthma and occupation in the 1958 birth cohort. Thorax (2013) 0.85
The GABRIEL Advanced Surveys: study design, participation and evaluation of bias. Paediatr Perinat Epidemiol (2011) 0.84
Health-related quality of life in rural children living in four European countries: the GABRIEL study. Int J Public Health (2012) 0.84
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84
Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83
CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83
Concise guidance: diagnosis, management and prevention of occupational asthma. Clin Med (2012) 0.83
Smoking cessation and associated factors during pregnancy. Gac Sanit (2004) 0.83